To explore the guiding value of multi-geneloci detection for chemotherapy in elderly patients with non-small cell lung cancer (NSCLC).

84 elderly patients with NSCLC admitted to Zhejiang Hospital from May 2016 to May 2018 were divided into control group and observation group on average. The control group was given conventional chemotherapy directly, the observation group detected the relevant genes (including ERCC1, ABCB1, CYP2D6, GSTP1, MTHFR, nudt15, UGT1A1 and XPC), and then formulated the chemotherapy scheme according to the gene detection results. Three weeks was one chemotherapy cycle, with a total of two cycles. After treatment, the short-term efficacy, adverse reactions and related tumor markers were compared between the two groups. T test was used to compare the measurement data between groups, and χ² test was used for comparison of enumeration data.

After treatment, the objective effective rate was 47.62% in the observation group and 26.19% in the control group, the difference was statistically significant (χ²=4.140, P < 0.05); the disease control rate was 83.33% in the observation group and 73.81% in the control group, the difference was not statistically significant(χ²=1.130, P > 0.05). Before treatment, there was no significant difference in all indexes between the two groups (P > 0.05); After treatment, there were significant differences in CEA and CA125 between the two groups (t=9.852, 17.837, P < 0.05). There were significant differences in the occurrence of gastrointestinal reactions, leukopenia and anemia between 2 groups (χ²=3.880, 4.200, 7.110, P < 0.05).

Using multi-geneloci detection to guide the application of chemotherapeutic drugs in elderly patients with NSCLC is not only highly targeted, but also can improve the short-term curative effect and reduce the occurrence of adverse reactions.